Author:
Andharia Mudra,Rai Jasuma,Shah Monali,Sonavane Priyanka
Abstract
Antimicrobials have traditionally been the only chemotherapeutic option for treating periodontitis and peri-implant disorders. With a growing understanding of the host–pathogen interactions in periodontal pathogenesis, novel therapeutic options for periodontitis and peri-implant disorders are developed by focusing on the host response with host-modulating drugs. When employed as host-modifying agents, a variety of sub-antimicrobial dose doxycycline (SDD), bisphosphonates and non-steroidal anti-inflammatory drugs were found to be successful in both experimental animal research and human trials. The current state and future prospects of host modulatory agents used to treat peri-implant disease are discussed in this evidence-based review.
Reference68 articles.
1. Long-term implant survival and success: A 10-16-year follow-up of non-submerged dental implants;Simonis;Clin Oral Implants Res,2010
2. Peri-implant mucositis and peri-implantitis: Clinical and histopathological characteristics and treatment;Khammissa;SADJ,2012
3. An insight into peri-implantitis: A systematic literature review;Wilson;Prim Dent J,2013
4. Peri-implant diseases: Consensus Report of the Sixth European Workshop on Periodontology;Lindhe;J Clin Periodontol,2008
5. Host modulation therapy – A promising new concept in treating periodontal diseases;Deshmukh;Int J Dent Clin,2011